EP4169522A1 - Composition pharmaceutique contenant une fraction de saururus chinensis, et procédé de préparation de celle-ci - Google Patents

Composition pharmaceutique contenant une fraction de saururus chinensis, et procédé de préparation de celle-ci Download PDF

Info

Publication number
EP4169522A1
EP4169522A1 EP21826722.7A EP21826722A EP4169522A1 EP 4169522 A1 EP4169522 A1 EP 4169522A1 EP 21826722 A EP21826722 A EP 21826722A EP 4169522 A1 EP4169522 A1 EP 4169522A1
Authority
EP
European Patent Office
Prior art keywords
saururus chinensis
inflammatory bowel
aqueous solution
bowel disease
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21826722.7A
Other languages
German (de)
English (en)
Other versions
EP4169522A4 (fr
Inventor
Kwang-Soon Shin
Yang-Kook RHO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacobio Inc
Industry Academic Cooperation Foundation of Kyonggi University
Original Assignee
Pharmacobio Inc
Industry Academic Cooperation Foundation of Kyonggi University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacobio Inc, Industry Academic Cooperation Foundation of Kyonggi University filed Critical Pharmacobio Inc
Publication of EP4169522A1 publication Critical patent/EP4169522A1/fr
Publication of EP4169522A4 publication Critical patent/EP4169522A4/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • the present disclosure relates to a preparation method of an active fraction of Saururus chinensis.
  • the present disclosure also relates to a pharmaceutical composition comprising a solvent fraction of Saururus chinensis prepared by a specific preparation method.
  • the present disclosure further relates to a medical use of a solvent fraction of Saururus chinensis for treating inflammatory bowel disease.
  • Colitis is a disease in which inflammation occurs in the large intestine, and includes inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and the like.
  • IBD Inflammatory bowel disease
  • IBS irritable bowel syndrome
  • IBD Inflammatory bowel disease
  • UC ulcerative colitis
  • CD Crohn's disease
  • Mucosal biopsies of patients with IBD show increased expression of pro-inflammatory cytokines, chemokines, and ICAM-1 (Intercellular Adhesion Molecule 1) and loss of mucous, and a reduction in tight junctions between epithelial cells.
  • a representative drug currently used for the treatment of inflammatory bowel disease include 5-aminosalicylic acid, corticosteroid, immunomodulator, anti-tumor necrosis factor- ⁇ agent(anti TNF- ⁇ ), and the like. Because they exert their effects through mutually different mechanisms of action, they are used in stages according to clinical guidelines, but they do not appear to be a fundamental therapeutic drug, and various side effects have been reported.
  • Mucosal healing has recently emerged as a therapeutic goal of finflammatory bowel disease.
  • the greatest features of patients with inflammatory bowel disease is that mucosal production of the colon is lowered.
  • the absence of a mucous layer allows bacteria to reach the intestinal epithelial cells directly, which causes a severe inflammatory response.
  • mucosal production must be restored, and the robustness of tight junction between intestinal epithelial cells is also of great importance.
  • research on mucosal production has been actively conducted.
  • Saururus chinensis (also called Sambaekcho) is a perennial herbaceous plant belonging to the family Saururaceae, which is known in folklore to have various effects in the whole plant or the roots and leaves.
  • a method for preparing a solvent fraction of Saururus chinensis (SCEP2) effective for inflammatory bowel disease comprising the steps of:
  • the enzyme serves to separate the active polysaccharide component present in Saururus chinensis, and preferably, one or more enzymes selected from the group consisting of pectinase (or polygalacturonase), pectinesterase, pectin lyase, arabinose, xylanase, beta-glucanase, cellulase can be used alone or in combination. More preferably, the enzyme may be polygalacturonase, pectin lyase or a mixture thereof, and even more preferably, the enzyme is a mixture of polygalacturonase and pectin lyase.
  • the enzyme treatment may be performed by adding 0.05-5 parts by weight of the enzyme based on parts by weight of Saururus chinensis.
  • the amount of enzyme is less than 0.05 parts by weight, the amount of enzyme is too small, and the recovery rate of active polysaccharides present in Saururus chinensis is reduced, and when the amount of enzyme exceeds 5 parts by weight, the efficacy of the active polysaccharide may be lowered due to excessive enzyme action, which is thus not preferable.
  • the reaction time during the enzymatic treatment is preferably 6-96 hours, more preferably 12-72 hours.
  • the temperature and pH under the enzymatic treatment are applied under optimal conditions for each enzyme, thereby capable of obtaining the active polysaccharide component with the highest recovery rate, which is thus preferable.
  • the enzyme treatment reaction time is less than 6 hours, the time required for the enzyme treatment is too short, reducing the recovery rate, and when the reaction time is more than 96 hours, the efficacy of the active polysaccharide may be lowered due to excessive enzyme treatment, which is thus not preferable.
  • the step S5 is a step of concentrating the filtrate, adding more (preferably, 2-8 times by volume) ethanol than the concentrate and stirring the mixture to form a precipitate.
  • the precipitate may be formed by allowing the reaction solution to stand still.
  • the step of obtaining the precipitate of the step S6 can be performed, for example, by centrifugation.
  • the recovered precipitate can be used as a raw material for producing pharmaceuticals after concentration and freeze-drying.
  • a method for preparing a solvent fraction of Saururus chinensis (SCESII-1) effective for inflammatory bowel disease comprising the steps of:
  • the three solvent fractions can be obtained as follows.
  • Fraction 1 (SCESII-1): Elution is started with 20-40 volume% (preferably 30%) ethanol, and stops recovery when the recovered eluate reaches a bed volume of approximately 1.5-2.5 (preferably 2 times) ethanol, and the elution solvent is changed to 60-80 volume% (preferably 70%) ethanol. It is a fraction until the elution solvent is changed to 60-80 volume% ethanol.
  • the eluate is allowed to flow at room temperature at a flow rate at which a bed volume (BV) of one time per unit time flows, and the eluate is recovered.
  • BV bed volume
  • Fraction 2 (SCESII-2): Elution is started with 60-80 volume% (preferably 70%) ethanol and recover it. When the eluate reaches a bed volume (BV) of about 1.5-2.5 (preferably 2 times), the recovery is stopped, and the elution solvent is changed to 100% ethanol.
  • BV bed volume
  • a method for preparing a solvent fraction of Saururus chinensis (SCESII-4) effective for inflammatory bowel disease comprising the steps of:
  • Saururus chinensis extract has various effects such as antioxidation, anti-cancer, and anti-inflammatory effects, but according to the results confirmed by the present inventors, the conventional Saururus chinensis extract had almost no effect on inflammatory bowel disease. However, unusually, the solvent fraction of Saururus chinensis obtained by a specific preparation method exhibited a surprising effect in treating or ameliorating inflammatory bowel disease, unlike the conventional Saururus chinensis extract.
  • the present inventors confirmed that the active solvent fraction Saururus chinensis prepared by a specific preparation method exhibits effects such as therapeutic effects on DSS-induced colitis inmice, anti-inflammation effects, increased mucin production capacity, and enhanced tight junction robustness of intestinal epithelial cells, and confirmed its usefulness in the treatment of inflammatory bowel disease through examination of colon tissue induced by inflammatory bowel disease with DSS.
  • the present inventors further confirmed that the solvent fraction of Saururus chinensis by a specific preparation method according to the present disclosure inhibits the activity of inflammatory cytokines TNF-a, IL-1 ⁇ , IL-6, etc., thereby completing the present disclosure.
  • Saururus chinensis As for the Saururus chinensis, Saururus chinensis (Sambaekcho) belonging to the family Saururaceae can be used.
  • the aqueous ethanol solution is 60-80 volume% ethanol aqueous solution. More preferably, in the methods 1 to 3 according to the present disclosure, the aqueous ethanol solution is 65-75 volume% ethanol aqueous solution.
  • the residue recovered in the step S1 can be extracted similarly under the extraction conditions of step S1 to recover the extract, and this extract can be used in combination with the extract in step S1.
  • High porous type synthetic adsorbent of Styrene and DVB (Divinyl benzene) copolymer e.g., Amberlite XAD-2, Amberlite XAD-4, Amberlite XAD-16N, Amberlite XAD-1180N, TRILITE ® GSH-20, TRILITE GSP-25 TRILITE GSP-50, TRILITE GSP-07, DIAION HP20
  • porous synthetic adsorbent of nonionic aliphatic acrylic polymer e.g., Amberlite XAD-7HP
  • DIAIONs HP20 is used as the resin.
  • the solvent fraction of Saururus chinensis according to the present disclosure can be prepared in a powder state using a conventional drying method such as vacuum drying, spray drying, or freeze drying.
  • the solvent fraction of Saururus chinensis may be in the form of a concentrated liquid or lyophilized powder.
  • the solvent fraction of Saururus chinensis according to the present disclosure may be a soft extract in concentrated liquid form.
  • the present disclosure also provides a pharmaceutical or health functional food composition comprising a solvent fraction of Saururus chinensis, which is obtained by any one of the methods 1 to 3 according to the present disclosure.
  • the present disclosure further provides a pharmaceutical or health functional food composition for preventing, treating or ameliorating inflammatory bowel disease, comprising a solvent fraction of Saururus chinensis, which is obtained by any one of the methods 1 to 3 according to the present disclosure.
  • inflammatory bowel disease is a generic term for diseases that cause inflammation in the intestine tract, and specifically, it may be a chronic recurrent inflammatory disease caused by dysregulation of the immune system in the small intestine and/or large intestine.
  • the inflammatory bowel disease includes ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), and the like.
  • the pharmaceutical or health functional food composition of the present disclosure can be formulated into in a dosage form for oral administration, for example, tablets, troches, lozenges, water-soluble or oily suspensions, powders or granules, emulsions, hard or soft capsules, syrups or elixirs, or the like according to a conventional method for preventing or treating inflammatory bowel disease.
  • excipients such as lactose, saccharose, sorbitol, mannitol, starch, lactose, microcrystalline cellulose, etc.
  • binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.
  • disintegrants such as dicalcium phosphate, crospovidone, etc.
  • lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol wax, etc.
  • liquid carriers such as fatty oil may be contained in addition to the above-mentioned materials.
  • the pharmaceutical composition of the present disclosure may be parenterally administered.
  • the parenteral administration may be performed by means of subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection method.
  • said composition may be prepared into solution by being mixed in water with stabilizers or buffer agents, and then may be formulated again into a unit form for administration of ampoule or vial.
  • a dosage of the pharmaceutical or health functional food composition according to the present disclosure need to be an amount effective to exhibit sufficient therapeutic or prophylactic effects.
  • the term "effective amount" refers to an amount which is sufficient to treat the disease at a reasonable benefit/risk ratio applicable to medical treatment, and a level of effective dose may be variously selected by those skilled in the art according to factors such as a formulation method, a patient's condition, weight, gender and age, a severity of di sease, a drug form, an administration route and period, an excretion rate, reaction sensitivity, etc.
  • the effective amount may vary depending on a route of treatment, a use of excipients and a possibility of being used with other drugs, as recognized by those skilled in the art.
  • a dosage or dose of the solvent fraction of Saururus chinensis according to the present disclosure may be diversified according to a patient's age, physical condition, body weight, etc., but may be preferably administered within a range of 10 to 100 mg/kg (body weight)/day in general. And such administration may be performed once a day or divided into several times a day within the range of daily effective inputs.
  • the health functional food composition according to the present disclosure can be ingested by being included in various foods.
  • it can be ingested by being included in meats, sausages, breads, chocolates, candies, snacks, confectioneries, pizzas, instant noodles, other noodles, chewing gums, dairy products including ice creams, various types of soup, beverages, teas, health drinks, alcohol beverages, vitamin complexes and the like.
  • a method for treating, preventing or ameliorating inflammatory bowel disease comprising administering a pharmaceutically or prophylactically effective amount of the solvent fraction of Saururus chinensis, which is prepared by a specific preparation method of the present disclosure, to an individual in need of treatment, prevention or amelioration of inflammatory bowel disease.
  • the individual is human.
  • the present disclosure provides a method for preparing a solvent fraction of Saururus chinensis useful for the treatment, amelioration or prevention of inflammatory bowel disease.
  • the present disclosure also provides a pharmaceutical or health functional food composition for treating, ameliorating or preventing inflammatory bowel disease comprising as an active ingredient, a solvent fraction of Saururus chinensis prepared according to the preparation method of the present disclosure.
  • the dried and pulverized Saururus chinensis was mixed with 20-fold volume of purified water, and extracted at 100°C for 2 hours. After extraction, the residue was removed using an extraction cloth, and the extract was filtered with Whatman No.2 filter paper. The filtrate was concentrated using a vacuum concentrator, and then freeze-dried to prepare a Saururus chinensis hot water extract (SCW).
  • SCW Saururus chinensis hot water extract
  • Example 2 Preparation of various Saururus chinensis organic solvent extracts (SCE, SCESII-1, SCESII-2, SCESII-3, SCESII-4)
  • the dried and pulverized Saururus chinensis was mixed with 10-fold volume of 70% (v/v) ethanol aqueous solution, and extracted at 70°C for 2 hours. After filtration with an extraction cloth, the filtered residue was extracted once more under the same conditions.
  • the extract was filtered with Whatman No.2 filter paper and concentrated using a vacuum concentrator. This was called 70% ethanol extract concentrate SCE.
  • the SCE extract was passed through a column filled with synthetic resin HP20. All components that were not adsorbed to the resin were recovered using purified water. This component was called SCESII-4.
  • the components adsorbed to the resin were eluted in the order of purified water ⁇ 30 volume% ethanol, 30-70 volume% ethanol, and 70-100 volume% ethanol, and was recovered according to the polarity of the elution solvent. These were called SCESII-1, SCESII-2, and SCESII-3 according to the order in which they were first eluted.
  • Example 3 Preparation of Saururus chinensis crude polysaccharide SCEP1, active polysaccharide SCEP2 and low molecular saccharide SCES fractions
  • Saururus chinensis was extracted with 70% ethanol aqueous solution, and the remaining residue was again mixed with 20-fold volumes of purified water and stirred at 100°C for 2 hours.
  • Enzyme (1 : 1 weight ratio of Pectinex ® Ultra SP-L and Pectinex ® Ultra MASH) was added and reacted with stirring at 55°C for 72 hours.
  • the enzyme reaction solution was inactivated at 100°C for 30 minutes.
  • the extract was filtered with Whatman No.2 filter paper. This filtrate was called crude polysaccharide SCEP1. After the filtrate was concentrated, ethanol of 4 times the volume of the concentrate was added, stirred for 30 minutes, and then left at room temperature for 24 hours to form a precipitate.
  • the precipitate was centrifuged to recover the precipitate and the supernatant, respectively.
  • the recovered precipitate was concentrated and then freeze-dried to prepare a SCEP2 active polysaccharide fraction of Saururus chinensis, and the supernatant was concentrated and then freeze-dried to prepare a low molecular-weight sugar fraction of Saururus chinensis SCES.
  • the normal control group and the negative control group (NC) ingested singly with 5% DSS were dissolved in distilled water, and the sample group was dissolved in distilled water at the doses listed in Table 1 below, and administered orally once a day for 9 days.
  • the disease activity index was calculated based on the score shown in Table 2 below after visual confirmation of the weight loss, loose or soft stool, bloody stool, and the presence or absence of blood in the anus at intervals of 2 days.
  • DAI weight loss score + stool consistency score + blood in stool score + blood in anus score
  • DAI Disease activity index
  • the DAI score increased from day 2 of all groups except for the normal control group, but the low molecular active substance fraction SCESII-1 and the active polysaccharide fraction SCEP2 had a significantly lower DAI score than the negative control group (NC) on the 8th day, indicating an inhibitory effect on colitis.
  • the other solvent fractions and Saururus chinensis water extract had almost no effect.
  • DAI is measured using factors such as body weight, stool condition, and bloodstain level, and thus, the DAI could be a more important evaluation factor.
  • mice were sacrificed on the 10th day of the experiment, and the length of the large intestine and small intestine and the weight of the spleen were measured and evaluated. The results are collectively shown in FIG. 2 .
  • TNF- ⁇ and myeloperoxidase (MPO) contents were performed in colitis-induced colon tissues.
  • the colon tissue sample was placed in a lysis buffer (Intron, Seoul, Korea) and pulverized using a homogenizer (Scilogex, Rocky hill, CT, USA). This was centrifuged at 10,000 rpm, 4°C for 20 minutes to recover the supernatant and the TNF- ⁇ and MPO content was determined using an ELISA kit according to the manufacturer's instructions. The results are shown in FIG. 4 and FIG 5 .
  • mice 62 1-week-old C3H/HeN mice were divided into groups of 6 mice, and then, the solvent fraction of Saururus chinensis was orally administered a total of 10 times (once/2 days) for 20 days.
  • Peyer's patches cells of mice were recovered and cultured in a 96-well plate for 3 days, and sIgA produced by Peyer's patches cells activated by oral administration was analyzed by ELISA.
  • the small intestine of the mice after oral administration was removed and feces were collected, and the sIgA production ability was analyzed by ELISA. The results are shown in FIG. 6 .
  • the cecum of the mouse after oral administration was recovered, diluted with 80% methanol to have a final concentration of 1 g/mL, filtered with a 0.45 ⁇ m syringe filter, and the ability to produce five short-chain fatty acids acids (acetic acid, propionic acid, butyric acid, valeric acid and heptanoic acid) was confirmed through gas chromatography (GC) equipped with a DBFFAP capillary column. The results are shown in Table 4 below.
  • mice were provided with water containing 5% DSS for 7 days, and the experimental sample was orally administered for 8 days. After sacrificing the experimental animals, tissue analysis was performed. Sections of the large intestine were fixed with 10% formalin solution, then filled with paraffin, and mounted with Map balsam. Each slide was observed using an optical microscope (40Xmagnification). Images were analyzed using MetaMorph software (Molecular Devices, Sunnyvale, CA, USA). The results are shown in FIG. 7 .
  • the amount of Mucin (stained blue by Alcian Blue) secreted from the Goblet cells was recovered similar to that of the normal group, when compared with the normal group not treated with DSS.
  • the present disclosure relates to a composition for preventing, treating or ameliorating g inflammatory bowel disease containing a specific fraction prepared from Saururus chinensis as an active ingredient, and a method for preparing the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP21826722.7A 2020-06-17 2021-06-17 Composition pharmaceutique contenant une fraction de saururus chinensis, et procédé de préparation de celle-ci Pending EP4169522A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200073480A KR102499893B1 (ko) 2020-06-17 2020-06-17 삼백초 분획물을 포함하는 약학 조성물 및 이의 제조 방법
PCT/KR2021/007582 WO2021256865A1 (fr) 2020-06-17 2021-06-17 Composition pharmaceutique contenant une fraction de saururus chinensis, et procédé de préparation de celle-ci

Publications (2)

Publication Number Publication Date
EP4169522A1 true EP4169522A1 (fr) 2023-04-26
EP4169522A4 EP4169522A4 (fr) 2024-02-28

Family

ID=79176414

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21826722.7A Pending EP4169522A4 (fr) 2020-06-17 2021-06-17 Composition pharmaceutique contenant une fraction de saururus chinensis, et procédé de préparation de celle-ci

Country Status (6)

Country Link
US (1) US20230218701A1 (fr)
EP (1) EP4169522A4 (fr)
JP (1) JP2023531210A (fr)
KR (1) KR102499893B1 (fr)
CN (1) CN115715196B (fr)
WO (1) WO2021256865A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100569089B1 (ko) * 2002-07-20 2006-04-10 주식회사 엘컴사이언스 뇌기능 및 인지 기능 개선 활성을 갖는 조성물
KR20050076225A (ko) * 2004-01-20 2005-07-26 학교법인 인제학원 항산화 및 항염증 활성을 갖는 삼백초 추출물을 포함하는조성물
KR101116828B1 (ko) * 2009-02-07 2012-03-13 경북대학교 산학협력단 고 함량의 활성형 플라보노이드 화합물의 제조방법 및 이로부터 퀘르세틴의 간편 신속 분리 방법
WO2011099665A1 (fr) * 2010-02-12 2011-08-18 주식회사 케이씨아이 Composition antimicrobienne contenant des extraits d'ingrédients naturels, antiseptique naturel composite et procédé de fabrication associé
KR101403999B1 (ko) * 2012-06-20 2014-06-17 영남대학교 산학협력단 독성물질을 제거한 삼백초 정제물 및 분획물의 제조방법 및 상기 정제물을 유효성분으로 함유하는 천식 및 알러지성 질환의 치료 및 예방을 위한 조성물
KR101482661B1 (ko) * 2013-03-06 2015-01-19 경북대학교 산학협력단 삼백초(Ｓａｕｒｕｒｕｓ ｃｈｉｎｅｎｓｉｓ Ｌ.) 추출물을 함유하는 스트레스성 위염 억제용 조성물
KR101630908B1 (ko) * 2013-09-26 2016-06-15 충북대학교 산학협력단 사우서네올 d 화합물을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
KR20150142213A (ko) 2014-06-11 2015-12-22 인제대학교 산학협력단 삼백초 수용성 추출물을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
CN108601804A (zh) * 2015-11-06 2018-09-28 韩国科玛株式会社 用于预防和治疗炎性肠病的组合物
KR20170067055A (ko) * 2015-12-07 2017-06-15 인제대학교 산학협력단 삼백초의 수용성 추출물을 포함하는 Th-1 매개 질환의 치료 또는 예방용 약학적 조성물 및 이의 제조 방법
KR20200073480A (ko) 2018-12-14 2020-06-24 허승표 온도 조절과 흔들림 완화 기능을 갖춘 유모차
CN110467687A (zh) * 2019-09-24 2019-11-19 贵州道庄生物科技有限公司 一种白芨多糖胶提取工艺

Also Published As

Publication number Publication date
CN115715196A (zh) 2023-02-24
WO2021256865A1 (fr) 2021-12-23
JP2023531210A (ja) 2023-07-21
KR20210155944A (ko) 2021-12-24
EP4169522A4 (fr) 2024-02-28
US20230218701A1 (en) 2023-07-13
CN115715196B (zh) 2024-05-28
KR102499893B1 (ko) 2023-02-15

Similar Documents

Publication Publication Date Title
JP4777776B2 (ja) 酢を利用した人参製剤及びこれの製造方法
US8168238B2 (en) Extracts of Aquilaria hulls and use thereof in the treatment of cancer
KR101579219B1 (ko) 복합 추출물을 포함하는 대장염 예방, 개선 또는 치료용 조성물
RU2426552C2 (ru) Экстракты phaseolus vulgaris, их применение и композиции, содержащие их
WO2017148414A1 (fr) Fucoïdane, son procédé de fabrication et ses utilisations
AU2013210416B2 (en) Desrhamnosyl acteoside-containing olive extract
JP2001342142A (ja) 泌尿器系疾患予防治療用組成物
EP4169522A1 (fr) Composition pharmaceutique contenant une fraction de saururus chinensis, et procédé de préparation de celle-ci
KR101466308B1 (ko) 지모 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 대장염 예방 또는 치료용 조성물
KR101119410B1 (ko) 회향근 추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물
KR101638776B1 (ko) 페어포바이드계 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 대사성 질환 또는 이들의 합병증의 예방 또는 치료용 조성물
KR101787082B1 (ko) 유효 사포닌 함량이 증가된 도라지 추출물을 유효성분으로 함유하는 류마티스 관절염 치료용 약학적 조성물
KR100779026B1 (ko) 염증성 질환 치료 및 예방에 유용한 구골 추출물
KR20190142672A (ko) 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물
KR20190048431A (ko) 백수오 조다당 추출물을 유효성분으로 함유하는 대장염의 예방, 개선 및 치료용 조성물
JP7168196B2 (ja) 腸管バリア機能向上剤
KR101093731B1 (ko) 맥문동추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물
JP2009269896A (ja) 抗糖尿病食品または医薬品素材及び抗糖尿病食品または医薬品
KR20230052732A (ko) 원산지가 다른 프로폴리스를 혼합사용하여 초임계 추출한 면역기능개선 건강기능식품 조성물 및 그 제조방법
EP4216975A1 (fr) Compositions à base de plantes synergiques pour l'immunité, le rhume et la toux
US20090291153A1 (en) Health food, Method for producing the same and dried Product and Extract
KR101333715B1 (ko) 마스티시아 알보리아 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR20140023862A (ko) 산수유 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 대장염 예방 또는 치료용 조성물
KR20240076704A (ko) 코디셉스 밀리타리스 또는 패실로마이세스 자포니카를 이용하여 발효시킨 인삼잎 유래 다당을 포함하는 염증성 장질환의 예방, 개선 및 치료, 면역증강 및 항암 조성물의 제조 방법
KR101629797B1 (ko) 백두옹 추출물 또는 이로부터 분리된 활성성분을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240125

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/105 20160101ALI20240119BHEP

Ipc: A61P 1/00 20060101ALI20240119BHEP

Ipc: A61P 29/00 20060101ALI20240119BHEP

Ipc: A61K 36/78 20060101AFI20240119BHEP